Sixth Element Capital is currently managing the £70m CRT Pioneer Fund (CPF) to create the future of cancer therapy and diagnosis.
Investment Type: Venture Capital
Mentions in press and media 2
| Date | Title | Description |
| 16.11.2017 | NeoPhore Raises £3M in Funding | NeoPhore Ltd, a spin out from Cambridge, UK – based PhoreMost Ltd., focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system, raised £3m in funding. Sixth Element Ca... |
| 09.04.2012 | EIF and Cancer Research Technology to Create £50M Investment Fund | European Investment Fund and Cancer Research Technology (CRT), Cancer Research UK’s commercial arm, have partnered to create a £50m investment fund to bridge the funding gap in the UK between cancer drug discovery and early development. CRT... |